'Hy's Law,' the 'Rezulin Rule,' and other predictors of severe drug-induced hepatotoxicity: Putting risk-benefit into perspective

Pharmacoepidemiology and Drug Safety

Volumn 15, Issue 4, 2006, Pages 221-229

  Lewis, James H ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BROMFENAC; CINCHOPHEN; DANTROLENE; DICLOFENAC; ENFLURANE; ETODOLAC; HALOTHANE; IBUFENAC; IPRONIAZID; ISOFLURANE; ISONIAZID; KETOCONAZOLE; LABETALOL; METHOXYFLURANE; NIMESULIDE; NITROFURANTOIN; OXAPROZIN; PARACETAMOL; PEMOLINE; PHENYLBUTAZONE; PHENYTOIN; PIROXICAM; PYRAZINAMIDE; SULINDAC; TIENILIC ACID; TROGLITAZONE; TROVAFLOXACIN; UNINDEXED DRUG; VALPROIC ACID;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; DISEASE SEVERITY; DRUG APPROVAL; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG OVERDOSE; DRUG RECHALLENGE; DRUG TOLERANCE; DRUG WITHDRAWAL; HUMAN; JAUNDICE; LIVER FAILURE; LIVER INJURY; LIVER NECROSIS; LIVER TOXICITY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

ALANINE TRANSAMINASE; ANTICOAGULANTS; AZETIDINES; BENZYLAMINES; BILIRUBIN; BIOLOGICAL MARKERS; CHROMANS; DRUG APPROVAL; HEPATITIS, TOXIC; HUMANS; HYPOGLYCEMIC AGENTS; JAUNDICE; LIVER; LIVER FAILURE, ACUTE; PHARMACOEPIDEMIOLOGY; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; THIAZOLIDINEDIONES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33646048007     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1209     Document Type: Article

References (86)

1. Zimmerman HJ, Rosenblum L, Korn RJ, Feldman PE. Some preliminary clinical and biochemical aspects of liver function in patients receiving iproniazid. Ann NY Acad Sci 1959; 80: 915-927.
2. Harinasula U, Zimmerman HJ. Diphenylhydantoin sodium hepatitis. JAMA 1968; 203: 1015-1018.
3. Black M, Mitchell JR, Zimmerman HJ, Ishak KG, Epler GR. Isoniazid-associated hepatitis in 114 patients. Gastroenterology 1975; 69: 289-302.
4. Mitchell JR, Zimmerman HJ, Ishak KG, et al. Isoniazid liver injury: Clinical spectrum, pathology, and probable pathogenesis. Ann Int Med 1976; 84: 181-192.
5. Utili R, Boitnott JK, Zimmerman HJ. Dantrolene-associated hepatic injury. Incidence and character. Gastroenterology 1977; 72: 610-616.
6. Sharp JR, Ishak KG, Zimmerman HJ. Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin. Ann Int Med 1980; 92: 14-19.
7. Zimmerman HJ. Effects of aspirin and acetaminophen on the liver. Arch Int Med 1981; 141 (3 Spec No): 333-342.
8. Benjamin SB, Goodman ZD, Ishak KG, Zimmerman HJ, Irey NS. The morphologic spectrum of halothane-induced hepatic injury: Analysis of 77 cases. Hepatology 1985; 5: 1163-1171.
9. Zimmerman HJ. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. Appleton-Century-Crofts: New York 1978.
10. Zimmerman HJ. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on The liver,. Second edition. Lippincott Williams & Wilkins: Philadelphia, 1999.
11. Benjamin SB, Ishak KG, Zimmerman HJ, Grushka A. Phenylbutazone liver injury: A clinical-pathologic survey of 23 cases and review of the literature. Hepatology 1981; 1: 255-263.
12. Lewis JH, Zimmerman HJ, Benson GD, Ishak KG. Hepatic injury associated with ketoconazole therapy. Analysis 33 cases. Gastroenterology 1984; 86: 503-513.
13. Zimmerman HJ, Lewis JH, Ishak KG, Maddrey WC. Ticrynafen-associatede hepatic injury: Analysis of 340 cases. Hepatology 1984; 4: 315-323.
14. Zimmerman HJ, Ishak KG. Valproate-induced hepatic injury: Analysis of 23 fatal cases. Hepatology 1982; 2: 591-597.
15. Lewis JH, Zimmerman HJ, Ishak KG, Mullick FG. Enflurane hepatotoxicity. A clinicopathologic study of 24 cases. Ann Int Med 1983; 98: 984-992.
16. Nehra A, Mullick F, Ishak KG, Zimmerman HJ. Pemoline-associated hepatic injury. Gastroenterology 1990; 99: 1517-1519.
17. Clark JA, Zimmerman HJ, Tanner LA. Labetalol hepatotoxicity. Ann Int Med 1990; 113: 210-213.
18. Banks AT, Zimmerman HJ, Ishak KG, Harter JG. Diclofenac-associated hepatotoxicity: Analysis of 180 cases reported to the food and drug administration as adverse reactions. Hepatology 1995; 22: 820-827.
19. Tarazi EM, Harter JG, Zimmerman HJ, Ishak KG, Eaton RA. Sulindac-associated hepatic injury: Analysis of 91 cases reported to the Food and Drug Administration. Gastroenterology 1993; 104: 569-574.
20. Lewis JH. Drug-induced liver disease. Med Clin North Am 2000; 84: 1275-1311.
21. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003; 349: 474-485.
22. Graham DJ, Drinkard CR, Shatin D. Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone. Am J Gastroenterol 2003; 98: 175-179.
23. Graham DJ, Green L, Senior JR, et al. Troglitazone-induced liver failure: A case study. Am J Med 2003; 114: 299-306.
24. Watkins PB. Insight into hepatotoxicity: The troglitazone experience (editorial). Hepatology 2005; 41: 229-230.
25. Fontana RJ, McCashland TM, Brenner KG, et al. Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation. The Acute Liver Failure Study Group. Liver Transpl Surg 1999; 5: 480-484.
26. Hunter EB, Johnston PE, Tanner G, et al. Bromfenac (Duract)-associated hepatic failure requiring liver transplant. Am J Gastroenterol 1999; 94: 2299-2301.
27. Goldkind L, Laine L. A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: Lessons learned from the bromfenac experience. Pharmacoepidemiol Drug Saf 2005.
28. Food and Drug Administration. Public Health Advisor, 9 June 1999: Trovan (trovafloxacin/alatrovafloxacin mesylate). Accessed via: www.FDA.gov/cder/news/trovanadvisory.htm.
29. Clinical White Paper: Drug-induced liver toxicity. CDER-PhRMA-AASLD November 2000 accessed via www.fda.gov/cder/livertox/postmarket.pdf
30. Drug-induced liver injury conference, Chantilly, Virginia, February 12-13,2001 via website: fda.gov/cder/livertox/default.htm
31. Senior JR. Regulatory perspectives. In Drug-Induced Liver Disease. Kaplowitz N, DeLeve LD, (eds). Marcel Dekker, Inc.: New York, 2003; 739-754.
32. Meadows M. Serious liver injury: Leading reason for drug removals, restrictions. FDA Consumer Magazine May-June 2001; 1-3.
33. FDA Advisory Committee meeting on Ximelagatran, September 10, 2004 accessed via: www.fda.gov/ohrms/dockets/ac/transcripts/2004-4069T1.htm.
34. Lewis JH, Zimmerman HJ. Drug- and chemical-induced cholestasis. Clin Liver Dis 1999; 3: 433-464.
35. Mohi-ud-din R, Lewis JR. Drug- and chemical-induced cholestasis. Clin Liver Dis 2004; 8: 95-132.
36. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990; 11: 272-276.
37. Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323-1330.
38. Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997; 26: 664-669.
39. Lee WM. Assessing causality in drug-induced liver injury. J Hepatol 2000; 33: 1003-1005.
40. Faust TW, Reddy KR. Postoperative jaundice. Clin Liver Dis 2004; 8: 151-166.
41. Aithal GP, Rawlins MD, Day CP. Accuracy of hepatic adverse drug reaction reporting in one English health region. Br Med J 1999; 319: 1541-1544.
42. Faich GA, Moseley RH. Troglitazone (Rezulin) and hepatic injury. Pharmacoepidemiol Drug Saf 2001; 10: 537-547.
43. Trontell A. Expecting the unexpected - drug safety, pharmacovigilance, and the prepared mind. N Engl J Med 2004; 351: 1385-1387.
44. Eger EI II, Smuckler EA, Ferrell LD, et al. Is enflurane hepatotoxic? Anesth Analg 1986; 65: 1986.
45. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med 1998; 338: 916-917.
46. St Peter JV, Neafus KL, Khan MA, Vessey JT, Lockheart MS. Factors associated with the risk of liver enzyme elevations in patients with type 2 diabetes treated with a thiazolidinedione. Pharmacotherapy 2001; 21: 183-188.
47. Bissell DM, Gores GJ, Laskin DL, Hoofnagle JH. Drug-induced liver injury: Mechanisms and test systems. Hepatology 2001; 33: 1009-1013.
48. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994; 271: 992-998.
49. Masubuchi Y, Bourdi M, Reilly TP, Graf ML, George JW, Pohl LR. Role of interleukin-6 in hepatic heat shock protein expression and protection against acetaminophen-induced liver disease. Biochem Biophys Res Commun 2003; 304: 207-212.
50. Lauterburg BH, Smith CV, Todd EL, Mitchell JR. Pharmacokinetics of the toxic hydrazine metabolites formed from isoniazid in humans. J Pharm Exp Ther 1985; 235: 566-570.
51. Gracon SI, Knapp MJ, Berghoff WG, et al. Safety of tacrine: Clinical trials, treatment IND, and postmarketing experience. Alzheimer Dis Assoc Disord 1998; 12: 93-101.
52. Blackard WG, Jr., Sood GK, Crowe DR, Fallon MB. Tacrine. A cause of fatal hepatotoxicity? J Clin Gastroenterol 1998; 26: 57-59.
53. Ballet F. Hepatotoxicity in drug development: Detection, significance and solutions. J Hepatol 1997; 26(suppl 2): 26-36.
54. O'Brien PJ, Chan K, Silber PM. Human and animal hepatocytes in vitro with extrapolation in vivo. Chem Biol Interact 2004; 150: 97-114.
55. FDA Working Group. Nonclinical assessment of potential hepatotoxicity in man. 2000. Via www.fda.gov/cder/livertox/preclinical.pfd
56. Weinshilboum. Inheritance and drug response. N Engl J Med 2003; 348: 529-537.
57. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-549.
58. Lewis JH. The rational use of potentially hepatotoxic medications in patients with underlying liver disease. Expert Opin Drug Saf 2002; 1: 159-172.
59. Hoofnagle JH. Drug-induced liver injury network (DILIN). Hepatology 2004; 40: 773.
60. Martin K, Begaud B, Latry P, et al. Differences between clinical trials and postmarketing use. Br J Clin Pharmacol 2004; 57: 86-92.
61. Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: Evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 2002; 25: 815-821.
62. Lebovitz HE. Differentiating members of the thiazolidinedione class: A focus on safety. Diabetes Metab Res Trev 2002; 18(Suppl. 2): S23-S29.
63. Freid J, Everitt D, Boscia J. Rosiglitazone and hepatic failure. Ann Int Med 2000; 132: 164.
64. Editor's note: Correction: Liver injury and rosiglitazone. Ann Int Med 2000; 133: 237.
65. FDA Metabolic and Endocrine Advisory Committee Briefing Document: Pioglitazone HCl tablets, April 7, 1999.
66. Pfeffer MA, Keech A, Sachs FM, et al. Safety and tolerability of pravastatin in long-term clinical trials. Circulation 2002; 105: 2341-2346.
67. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol 2003; 92: 152-160.
68. Aspinall MB, Whittle J, Aspinall SL, Maher RL, Jr., Good CB. Improving adverse-drug-reaction reporting in ambulatory care clinics at a Veterans Affairs hospital. Am J Health Syst Pharm. 2002; 59: 841-845.
69. Chan KA, Truman A, Gurwitz JH, et al. A cohort study of the incidence of serious liver injury in diabetic patients treated with hypoglycemic agents. Arch Int Med 2003; 163: 728-734.
70. El-Serag HE, Everhart JE. Diabetes increases the risk of acute hepatic failure. Gastroenterology 2002; 122: 1822-1828.
71. Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the US. Ann Int Med 2002; 137: 947-954.
72. Lee WM. Acetaminophen and the U.S. Acute Liver Failure Study Group: Lowering the risks of hepatic failure. Hepatology 2004; 40: 6-9.
73. Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug-induced liver injury in the United States. Liver Transpl 2004 10: 1018-1023.
74. Marino G, Zimmerman HJ, Lewis JH. Management of drug-induced liver disease. Curr Gastroenterol Rep 2001; 3: 38-48.
75. Adams PC, Arthur MJ, Boyer TD, et al. Screening in liver disease: Report of an AASLD clinical workshop. Hepatology 2004; 39: 1204-1212.
76. Kaplowitz N. Drug-induced liver injury. Clin Infect Dis 2004; 38(suppl 2): S44-S48.
77. Graham DJ, Drinkard CR, Shatin D, et al. Liver enzyme monitoring in patients treated with troglitazone. JAMA 2001; 286: 831-833.
78. Cluxton RJ, Jr., Li Z, Heaton PC, et al. Impact of regulatory labeling for troglitazone and rosiglitazone on hepatic enzyme monitoring compliance: Findings from the State of Ohio Medicaid program. Pharmacoepidemiol Drug Saf 2005; 14(1): 1-9.
79. McNeill L, Allen M, Estrada C, Cook P. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: Improved completion rates but more hepatotoxicity. Chest 2003; 123: 102-106.
80. Lee WM, Larrey D, Olsson R, Lewis JH, Keisu M, Auclert L, et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf 2005; 28: 351-370.
81. Anonymous. Is that it, then, for blockbuster drugs? Lancet 2004; 364: 1100.
82. CDER/CBER Risk management public workshop April 9-11, 2003, Washington, DC via www.fda.gov/cder/meeting/risk-Management.htm
83. Marcellino K, Kelly WN. Potential risks and prevention, part 3: Drug-induced threats to life. Am J Health Syst Pharm 2001; 58: 1399-1405.
84. Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2003; 289: 1154-1156.
85. Peterson HB, Thacker SB, Corso PS, Marchbanks PA, Koplan JP. Hormone therapy. Making decisions in the face of uncertainty. Arch Int Med 2004; 164: 2308-2312.
86. Miller HI. The curse of too much caution (editorial). The Wall Street J 2004; CCXLIV: A7.